Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-randomized, Multi-center Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1018 in Patients With Advanced Solid Tumors

NCT04928612 is registered in ClinicalTrials.gov with Coherent Biopharma (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT04928612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04928612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-randomized, Multi-center Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1018 in Patients With Advanced Solid Tumors
Lead sponsor
Coherent Biopharma (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
November 4, 2021
Completion date
December 31, 2024
Enrollment
170 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor